What’s next for #IRT systems? Explore the future of system flexibility, integration, and more at #IRT2024. ow.ly/l2bL50TlGXO

Meet ICON experts at #ESMO24, booth #423 to learn about our Centre for Paediatric Clinical Development’s expertise in supporting oncology studies involving paediatric participants including neonates, children, adolescents, young adults, and pregnant women. ow.ly/YAwc50T7uLY

ICON’s Outcome Measures service integrates DHTs and Patient-Reported Outcomes to capture the full impact of treatments on patients' lives. Learn more: ow.ly/vhSk50Tl5eQ

Join our webinar on 17 September at 11:00 EST to learn about survival analysis for immature data. Click here to register today: ow.ly/VJuy50SKHAy #HealthEconomics #HEOR

Medicare Part D Price Negotiations are impacting all areas of pharma. Learn how manufacturers should prepare for the overall impact to the industry on Sept 20 at 11 am. Sign up for the webinar. ow.ly/T00e50T3aew

Join ICON’s cardiac safety experts Dr. Polina Voloshko and Dr. Timothy Callahan who will discuss how long-term cardiovascular data can support a cardiac safety portfolio, exploring new cardiac monitoring technologies and their applications. Register: ow.ly/Agck50Tghyo

Seamless, 24/7 support is vital to smooth clinical trial operations. Learn how our global clinical trial help desk helps you navigate the complexities of clinical trials with confidence: ow.ly/WP9r50TmCkz

Listen to our latest Bioanalysis Zone podcast where we discuss the emerging trends in the field of immunogenicity and how they may shape the future of therapeutic protein development. ow.ly/Af9350SFNjX #immunogenicity

Are you ready to discuss the latest strategies for operational success in clinical trials? Pass by booth #20 at #OCTNordics in Copenhagen, Denmark to learn more. ow.ly/Ffxs50T1K6F

An atypical study with limited data, inconsistent dosing and only 12 patients: our case study shows how a small biotech developing a rare disease treatment overcame challenges to secure FDA approval, with help from ICON. Download it here. ow.ly/lt4350TiPpG

Meet Melissa Gottschlich at the #GSSS, during her session: Impact of technology on Trial Efficiency on September 28 at 10:45 am. ow.ly/BfNx50T9vKI

Leverage the industry's most experienced reader network of cardiovascular (CV) physicians and experts who will help you navigate the latest changes in cardiac safety trial requirements. Find out how we can help you: ow.ly/Ap1p50T8z2Y

Gain insights into biomarker approaches & accelerate timelines in drug development for oncology and immuno-related therapies at #BiomarkersEU. Visit the ICON team at booth #26. ow.ly/k6f350Tp4Ro

Every 1.5 minutes a child dies from cancer. That makes childhood cancer the leading non-communicable disease killer of children around the world, regardless of where they live. ow.ly/gVqs50T9BTY #ChildhoodCancerAwarenessMonth

In this Spotlight hosted by @Bioanalysis Zone we explore the elements involved in the different approaches for immunogenicity assessment to determine ADAs for different compounds/antibody modalities. ow.ly/Rwfy50SCg08

Medicare Part D Price Negotiation results for the ten drugs selected in the first round have been announced, and the list of the next 15 selections are scheduled for release on October 1, 2024. Learn the impact on industry in our blog: ow.ly/iqxg50Tl1T5

ICON understands the rapidly advancing landscape and the unique challenges of navigating the patient, site, product, and regulatory journeys in delivering CGT therapies. Arrange a meeting with us at #CGMesa24 on the Partnering One portal. ow.ly/aQX350TiR1S

Early collaboration with Regulatory CMC experts ensures compliance, minimises risk and accelerates timelines for biologics development. Explore the benefits for ATMP and CGT in our article: ow.ly/XVS950TpNuS

Read the latest research from Symphony Health, an ICONplc company, on a study that assesses the adherence and discontinuation of GLP-1 receptor agonists and SGLT-2 inhibitors among adult patients with T2D in the United States. ow.ly/9InT50TggY1

Listen to our recent webinar where we discuss considerations for Oligonucleotide therapeutics in CMC. ow.ly/Rwjo50TjW0g